Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass
Study Identifier:
2000099
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: pexelizumab
Date
Jan 2002 - Mar 2003
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: pexelizumab
Date
Jan 2002 - Mar 2003
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
During a heart bypass procedure, a substance called "complement" is released by the body. This complement causes inflammation, which can lead to side effects such as chest pain, heart attacks, heart failure, or impairment of memory, language and motor skills. The purpose of this study is to find out if the study drug (pexelizumab), which blocks complement release, can reduce such side effects and be taken safely.
Trial Locations
Location
Status
Location
Baptist Medical Center Cardiology
Birmingham, Alabama, United States, 35211
Status
N/A
Location
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35249-6880
Status
N/A
Location
IMC-Diagnostic and Medical Clinic
Mobile, Alabama, United States, 36604
Status
N/A
Location
Desert Samaritan - Lutheran Heart
Mesa, Arizona, United States, 85202
Status
N/A
Location
Good Samaritan Regional Medical Center
Phoenix, Arizona, United States, 85006
Status
N/A
Location
Saguaro Clinical Research
Tucson, Arizona, United States, 85712
Status
N/A